The US regulator has sent a Complete Response Letter (CRL) to French allergy specialist DBV Technologies (Euronext: DBV), setting back plans for the firm’s peanut allergy candidate Viaskin Peanut (DBV712).
The announcement hollowed shares in the Montrouge-based biotech firm, while stock in competitor Aimmune Therapeutics (Nasdaq: AIMT) were given a boost.
DBV has been developing the once-daily epicutaneous patch to treat peanut allergies in children ages four to 11 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze